Pharmaceuticals

The most-up-to-date pharmaceutical news stories, including medical, cosmetic, and supplemental treatments. This section contains releases covering all aspects of the pharmaceutical sector, from research, development, and testing, through to product launches and marketing. Topics include clinical trials and studies, as well as updates on the approval process for new treatment options. Learn about upcoming events, conferences, and educational initiatives. Also included is financial and corporate information from the sector, such as board decisions, appointments and changes, industry awards, and quarterly reports.

Latest

20 Nov, 2024, 22:31 GMT Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight

Chronic refractory cough (CRC) is characterized by a cough that persists for more than 8 weeks, even with treatment following established protocols....

20 Nov, 2024, 22:00 GMT Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced they have entered into a global strategic collaboration to...

20 Nov, 2024, 21:01 GMT Innocan Pharma Reports Third Quarter 2024 Financial Results

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on...

20 Nov, 2024, 20:31 GMT BerGenBio Appoints Olav Hellebø as CEO

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...

20 Nov, 2024, 17:00 GMT GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products

GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce...

20 Nov, 2024, 13:50 GMT John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX® (collagenase clostridium histolyticum)

Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including...

20 Nov, 2024, 10:00 GMT BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly announce that...

20 Nov, 2024, 05:01 GMT AmacaThera Announces Phase 1 Results of First-in-Human Study with AMT-143, Exceeding Expectations and Paving the Way for a Novel Approach to Post-Operative Pain Relief

AmacaThera today announced results from its Phase 1 clinical trial of AMT-143, an innovative, non-opioid anesthetic, formulated with the company's...

19 Nov, 2024, 22:46 GMT Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight

DelveInsight's 'Celiac Disease Pipeline Insight 2024' report provides comprehensive global coverage of pipeline celiac disease therapies in various...

19 Nov, 2024, 22:31 GMT Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight

DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline systemic lupus...

19 Nov, 2024, 21:05 GMT Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company...

19 Nov, 2024, 17:47 GMT Abzena Expands Analytical Capabilities to Include GMP Cell-Based Potency Testing Across US & UK Sites

Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, announced the expansion of their early and late-phase...

19 Nov, 2024, 14:00 GMT Say Hello to 3.0: Datarithm Releases Latest Version of Inventory Management Solution

In a landscape marked by intense competition, rising costs, and stringent regulatory requirements, independent pharmacies face an array of challenges ...

19 Nov, 2024, 10:00 GMT Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program

Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system...

19 Nov, 2024, 08:30 GMT Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain

Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies in...

19 Nov, 2024, 07:18 GMT Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for...

19 Nov, 2024, 07:00 GMT Nagase Viita to Launch Injectable-grade Pharmaceutical Excipient "SUCROSE SG" in 2025

Nagase Viita Co., Ltd., a member of the NAGASE Group headquartered in Okayama Japan, is set to expand the line of SOLBIOTE (TM), saccharide-based...

18 Nov, 2024, 23:19 GMT Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets...

18 Nov, 2024, 16:11 GMT EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in ATB Therapeutics. The €54 million Series A funding round is aimed at...

18 Nov, 2024, 13:19 GMT VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates ...

18 Nov, 2024, 13:00 GMT Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia

Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular...

18 Nov, 2024, 11:00 GMT Abbott Opens State-of-the-Art Global Manufacturing Facility in Kilkenny, Ireland

Abbott (NYSE: ABT) today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with a ceremony attended by...

18 Nov, 2024, 08:00 GMT New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China...

18 Nov, 2024, 06:00 GMT Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark for its VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. This is the first...

18 Nov, 2024, 01:00 GMT Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

Rona Therapeutics, a leader in innovative RNA-based therapies, today presented positive results from the Phase 1 clinical trial of RN0191 at the...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE